MDCX Company Profile and Key Details

Medicus Pharma Ltd. Common Stock has 63.18 million shares outstanding. The public float is 59.82 million shares, elevated short interest at 5.60% of float. This equals 3.01 million shares. The short ratio is 2.09 days. Institutional investors hold 4.03% of the float. Insiders own 12.48%.

MDCX has shown weak momentum, losing -6.16% over the past week and -41.95% over the past quarter, though year-to-date performance is down -10.46%. Short-term trend indicators are bullishly aligned (SMA20 19.6%, SMA50 0.4%, SMA200 -43.72%). The stock’s 14-day RSI is 59.18 (neutral), while the ATR of 0.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -84.79% below its high and over 48.25% above its low. Average 10-day trading volume of 9.12 million shares is significantly above the 3-month average of 2.44 million, indicating heightened recent market interest.

The stock is currently mid-range between its 52-week high and low $0.15 and $3.05. With a market capitalization of about $3.58 million, Medicus Pharma Ltd. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.61). Key stats such as the average daily volume over the past year has been around 4.08 million shares, in line with its 52-week average. Headquartered in West Conshohocken, PA, Medicus Pharma Ltd. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Raza Bokhari, the company employs approximately 16 people and listed since November 15, 2024. Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases.

Wall Street analysts project EPS growth of 11.71% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $9.00. The high target offers 16775.0% upside. The low target suggests 5525.0% downside. The mean target is $25.20. This offers 15650.0% upside. Medicus Pharma Ltd. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 12, 2026, missed forecasts by 50.0%. The prior quarter beat by 72.22%. Over the last six quarters, Apple has recorded several small beats. These include 10.26% in August 11, 2025.

Medicus Pharma Ltd. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Medicus Pharma Ltd. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -26.2%, with price expected at $0.12 by September 25, 2026, within a range of $0.08 to $0.16 3-Month Outlook: Projected rise of 10.7%, reaching $0.18 by December 10, 2026, with a range of $0.07 to $0.27. 1-Year Outlook: Projected gain of 10.7%, with price at $0.18 by September 10, 2027, within a range of $0.00 to $0.00.

Medicus Pharma Ltd. Common Stock (NASDAQ:MDCX) shares are down -10.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medicus Pharma Ltd. Common Stock trading at a premium to the broader market with a P/E of -0.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.94, suggesting 15238.25% upside. Our AI forecast model points to short-term weakness (-26.2% over two weeks), a medium-term rise (10.7% over three months), and a longer-term gain (10.7% over one year), with expected trading ranges indicating moderate volatility.

Medicus Pharma Ltd. Common Stock trades at a P/E ratio of -0.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -7.1 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.15, also above market averages.